当医药创新与投资领域"最强大脑"齐聚新区，将带来怎样的前沿洞察？这个医药界的盛会，又为何选择 在第十届这样一个极富承前启后里程碑意义的节点落地江北新区？ 10月26日上午，第十届医药创新与投资大会于南京江北新区启幕。这场大会，由中国医药创新促进会及 香港交易所共同主办，吸引了包括4位两院院士在内的近千位学界、产业界及投资界大咖前来参会，其 中不乏先声药业、百济神州、恒瑞医药、绿叶生命科学集团等知名药企负责人，8款重磅创新药的临床 数据也在此披露首发。 医药创投"风向标"，十年首次落地南京 说起生物医药产业，似乎总离不开"创新""投资"两个关键词。 创新，是产业发展的源头活水，从全新靶点的发现，到革命性疗法的诞生，无不源于此；而投资，则是 将前沿技术变为普惠产品的关键，支撑着一款款新药走过漫长的研发与临床周期。 医药创新与投资大会，正是将这两个关键词结合。自2016年首届召开，就专注于探讨全球医药创新趋 势，为"政产学研用金"搭建合作平台，已成为国内医药创新与投资的"风向标"。 大会第十年，首次落地南京、来到新区，也带来更前瞻的议题。 为期2天的大会，开设诸多分论坛，聚焦抗肿瘤新药、基因与细胞治疗、AI赋能医药 ...

8:30-8:35 主持人:冯 岚 中国医药创新促进会驻会副会长 8:35-8:40 南京领导致辞 1 十年征程，创新永续，10月26-27日，第十届医药创新与投资大会将于南京丰大国际大酒店盛大举行。终版日程今日正式发布，汇集医药创新与投资领域的 顶尖智慧，关注全球医药研发最新动态，聚力共赢，共启新程。 市场论坛 并购论坛 分享论坛 国际化论坛 分会场7 分会场5 分会场6 前沿生物技术 非上市公司 非上市公司 路演专场 路演专场 路演专场 第十届医药创新与投资大会开幕式 第一阶段 致辞 8:40-8:45 任晋生 中国医药创新促进会副会长 / 先声药业集 有限公司董事长兼首席执行官 8:45-8:50 陈翊庭 香港交易所集团行政总裁 ● 10-26 AM 1 1 1 第二阶段 主旨报告 主持人:单国洪 中国医药创新促进会副会长候进 百济神州全球高级副总裁,大中华区、中亚及南 总经理 8:50-9:20 创新药物研发国家科技重大专项的战 1 考与实施路径 报告人:曹雪涛 第十四届全国政协教科卫体委员 副主任、中国工程院院士、创新药物研发国家科: 专项技术总师 9:20-9:50 病原体与大健康 报告人:饶子和 ...

Group 1 - The fifth Shenzhen Biopharmaceutical Innovation Conference was held, focusing on innovation and international development in the biopharmaceutical industry, aiming to promote high-quality integration and global cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area [1] - The conference attracted nearly 3,500 participants, including around 200 industry experts and representatives, with over 3,300 attending via online streaming [1] - The global pharmaceutical industry is undergoing significant changes, with advancements in AI technology shortening drug development cycles and accelerating the internationalization of Chinese pharmaceutical companies [1] Group 2 - The founder of Yaoduo, Li Jing, highlighted that the export of Chinese innovative drugs has become a norm, with the License-out transaction amount expected to exceed 400 billion yuan in 2024, and the first payment nearing 36 billion yuan [2] - Emerging fields such as ADC, bispecific antibodies, and cell therapy are becoming highlights for Chinese companies going global, with a shift from "engineering manufacturing" to "original innovation" [2] - The global pharmaceutical market is projected to reach 19 trillion yuan by 2027, with oncology, autoimmune, and metabolic fields remaining key growth drivers [2] Group 3 - A roundtable discussion focused on the implementation of the Class B medical insurance catalog, emphasizing the importance of drug economic evaluation, real-world data sharing, and a one-stop settlement mechanism for innovative drugs to benefit Chinese patients [3] - The biopharmaceutical industry in China is transitioning from "local innovation" to "global value," requiring technological innovation, capital support, policy backing, and international cooperation to gain a more significant position in the global pharmaceutical landscape [3] - The conference provided insights and practical strategies for the industry, facilitating efficient platforms for collaboration between enterprises and capital, as well as domestic and international partnerships [3]

Group 1 - The Hong Kong pharmaceutical ETF (513700.SH) increased by 3.14%, with major constituents such as Xintai Medical rising by 60%, Meizhong Jiahe by 26%, and Nuocheng Jianhua by 13% [1] - Yuan Da Pharmaceutical announced a milestone breakthrough in its clinical research for the innovative radioactive nuclide-conjugated drug (RDC) GPN02006 for diagnosing hepatocellular carcinoma (HCC), achieving high-quality imaging within 30 minutes of administration [1] - GPN02006 provides strong molecular imaging evidence for personalized treatment plans, addressing the clinical need for rapid diagnosis of HCC and improving early diagnosis rates and monitoring of recurrence and metastasis [1] Group 2 - Guojin Securities believes that innovative drugs in the Hong Kong stock market will be a key investment theme in 2025, driven by AI enabling shorter R&D cycles, reduced costs, and improved efficiency [2] - The recovery of investment and financing activities in the global pharmaceutical industry is beneficial for improving cash flow for innovative drug companies [2] - Anticipation of fiscal stimulus, including the imminent release of the "Class B Directory," may catalyze valuation and sentiment recovery in the sector [2]

19.7亿美元大单！恒瑞医药出海大消息，高纯的港股通创新药ETF(159570)再 获资金净申购超2400万元！还有哪些创新药企出海加速？ 【还有哪些创新药企正加速出海？】 值得关注的是，近期创新药企出海热度走高。据机构统计，2020-2024年我国创新药License-out交易至少发生262项，合计交易总金额在1500亿美元以上。 2025年截至3月17日，国内已发生至少19项License-out交易，累计交易总金额超过126.1亿美元。其中，单笔交易达10亿美元及以上的项目有6个，包括先为 达的GLP-1受体激动剂、先声药业的SIM0500、信达生物的IBI3009、映恩生物的AVZO-1418/DB-1418等产品组合。 | | | 2025年中国医药企业出海合作 | | | | --- | --- | --- | --- | --- | | 企业名称 | 合作方 | 药物/技术 | 付款金额 | 协议签署时间 | | 先为达生物 | Verdiva Bio | GLP-1受体激动剂组合 | 总交易额24.7亿美元 (含首付款7000万美元 | 2025年1月 | | | | (VBR-103/XW ...